Cited by 72Thyroid Disorders and TreatmentsAdrenal Hormones and DisordersPharmacogenetics and Drug Metabolism

Inhibition of the Type 2 Iodothyronine Deiodinase Underlies the Elevated Plasma TSH Associated with Amiodarone Treatment

Open access
Rosene, Matthew L., Wittmann, Gábor, Arrojo e Drigo, Rafael, Singru, Praful S., Lechan, Ronald M., Bianco, Antonio C.·2010·Endocrinology

Abstract

The widely prescribed cardiac antiarrhythmic drug amiodarone (AMIO) and its main metabolite, desethylamiodarone (DEA), have multiple side effects on thyroid economy, including an elevation in serum TSH levels. To study the AMIO effect on TSH, mice with targeted disruption of the type 2 deiodinase gene (D2KO) were treated with 80 mg/kg AMIO for 4 wk. Only wild-type (WT) mice controls developed the expected approximate twofold rise in plasma TSH, illustrating a critical role for D2 in this mechanism. A disruption in the D2 pathway caused by AMIO could interfere with the transduction of the T4 signal, generating less T3 and softening the TSH feedback mechanism. When added directly to sonicates of HEK-293 cells transiently expressing D2, both AMIO and DEA behaved as noncompetitive inhibitors of D2 [IC(50) of >100 μm and ∼5 μm, respectively]. Accordingly, D2 activity was significantly decreased in the median eminence and anterior pituitary sonicates of AMIO-treated mice. However, the underlying effect on TSH is likely to be at the pituitary gland given that in AMIO-treated mice the paraventricular TRH mRNA levels (which are negatively regulated by D2-generated T3) were decreased. In contrast, AMIO and DEA both exhibited dose-dependent inhibition of D2 activity and elevation of TSH secretion in intact TαT1 cells, a pituitary thyrotroph cell line used to model the TSH feedback mechanism. In conclusion, AMIO and DEA are noncompetitive inhibitors of D2, with DEA being much more potent, and this inhibition at the level of the pituitary gland contributes to the rise in TSH seen in patients taking AMIO.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/en.2010-0553

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rosene, M. L., Wittmann, G., Arrojo e Drigo, R., Singru, P. S., Lechan, R. M., & Bianco, A. C.
Affiliations
  • University of Miami (US)
  • Tupper Research Institute and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism (G.W., P.S.S., R.M.L.), Tufts Medical Center and Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts 02111
  • Division of Endocrinology, Diabetes, and Metabolism (M.L.R., R.A.e.D., A.C.B.), University of Miami Miller School of Medicine, Miami, Florida 33136
  • Tufts University (US)
Corresponding author
Bianco, Antonio C.
Venue
Endocrinology
Published
2010-10-06
Volume
151
Issue
12
Pages
5961-5970
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W1996253654
Cited by
72
References
39
Citations by year
2025: 2 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 9 · 2016: 6 · 2015: 7 · 2014: 5 · 2013: 5 · 2012: 7
FWCI
4.34
Type
journal article
Language
en
Open access
Locations
  • Endocrinology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (DK 37021, R01DK058538, R01DK037021, DK 58538, R56DK037021)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
amiodarone, desethylamiodarone, type 2 deiodinase, TSH elevation, thyroid-stimulating hormone, non-competitive inhibition, T3, thyrotropin-releasing hormone, pituitary gland, adverse drug reactions, antiarrhythmic drugs
MeSH terms
Iodothyronine Deiodinase Type II, Amiodarone, Animals, Anti-Arrhythmia Agents, Cell Line, Iodide Peroxidase, Mice, Inbred C57BL, Thyrotropin, Mice, Knockout, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review